Wall Street analysts expect that Nektar Therapeutics (NASDAQ:NKTR) will report $24.81 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest sales estimate coming in at $20.08 million and the highest estimate coming in at $35.50 million. Nektar Therapeutics reported sales of $152.93 million during the same quarter last year, which indicates a negative year-over-year growth rate of 83.8%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 6th.

On average, analysts expect that Nektar Therapeutics will report full year sales of $1.17 billion for the current fiscal year, with estimates ranging from $1.12 billion to $1.20 billion. For the next financial year, analysts forecast that the company will post sales of $457.12 million per share, with estimates ranging from $135.00 million to $1.18 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.22 by $0.11. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the previous year, the firm posted ($0.39) EPS. The business’s revenue for the quarter was up 3043.7% compared to the same quarter last year.

NKTR has been the subject of a number of analyst reports. HC Wainwright reduced their price objective on Nektar Therapeutics to $97.00 and set a “buy” rating for the company in a research report on Monday, June 4th. JPMorgan Chase & Co. reduced their price objective on Nektar Therapeutics from $90.00 to $78.00 and set an “overweight” rating for the company in a research report on Monday, June 4th. ValuEngine lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. William Blair restated a “buy” rating on shares of Nektar Therapeutics in a research report on Monday, June 4th. Finally, BidaskClub upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 19th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Nektar Therapeutics presently has an average rating of “Buy” and an average price target of $82.91.

NASDAQ:NKTR opened at $59.00 on Friday. Nektar Therapeutics has a 12-month low of $21.75 and a 12-month high of $111.36. The company has a market cap of $10.08 billion, a P/E ratio of -107.27 and a beta of 2.27. The company has a quick ratio of 19.55, a current ratio of 19.67 and a debt-to-equity ratio of 0.13.

In other Nektar Therapeutics news, Director Jeffrey Robert Ajer sold 6,750 shares of the business’s stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $56.76, for a total transaction of $383,130.00. Following the completion of the transaction, the director now owns 15,750 shares in the company, valued at approximately $893,970. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Howard W. Robin sold 43,334 shares of the business’s stock in a transaction on Monday, June 25th. The stock was sold at an average price of $51.82, for a total value of $2,245,567.88. Following the transaction, the chief executive officer now owns 267,690 shares of the company’s stock, valued at approximately $13,871,695.80. The disclosure for this sale can be found here. Insiders have sold a total of 269,334 shares of company stock valued at $14,508,848 in the last quarter. 4.31% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in NKTR. HRT Financial LLC acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at $421,000. Advisors Asset Management Inc. acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at $373,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at $3,130,000. HighPoint Advisor Group LLC lifted its holdings in shares of Nektar Therapeutics by 66.4% in the second quarter. HighPoint Advisor Group LLC now owns 11,335 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 4,522 shares during the period. Finally, WINTON GROUP Ltd lifted its holdings in shares of Nektar Therapeutics by 41.1% in the second quarter. WINTON GROUP Ltd now owns 7,685 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 2,238 shares during the period. Institutional investors own 92.21% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Featured Story: What is a Call Option?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.